Xenon (XENE) Q2 Earnings Miss, Pipeline in Focus, Stock Down

Xenon Pharmaceuticals Inc. (XENE) reported a loss of 75 cents per share for the second quarter of 2024, wider than the Zacks Consensus Estimate of a loss of 72 cents. The company had incurred a loss of 72 cents per share in the year-ago quarter. In the reported quarter, Xenon did not generate any revenues. Due to the absence of a marketed product, the company only recognizes periodic collaboration revenues in its top line from its ongoing partnership with Neurocrine Biosciences (NBIX) for XEN901, now known ...